Global

Recent News Releases

CSL Behring News Releases

CSL Behring Subscribe to alerts

CSL Limited Financial News


29 October 2017
Data on the Preventive Effects of HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) in Subjects with Very Frequent HAE Attacks Presented by CSL Behring at the 2017 ACAAI Annual Scientific Meeting
Data on the preventive effects of HAEGARDA®, from a subgroup analysis from the Phase III COMPACT trial, presented at ACAAI 2017 Scientific Meeting. More.

24 October 2017
New Data for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) to be presented at the 2017 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
New data being presented at ACAAI Annual meeting highlighting preventive effect of HAEGARDA in HAE patients with a high frequency of attacks. More.

12 October 2017
CSL Behring Trains Employees to Save Lives in Their Communities and Workplace with CPR; AHA Encourages Other Businesses to Do the Same
CSL Behring is taking its workplace wellness initiatives to a whole new level by providing the American Heart Association’s (AHA) Hands-Only™ cardiopulmonary resuscitation (CPR) training to employees. More.

Media Resources

CSL Behring Company Information CSL Behring
Company Information >
CSL Behring Media Contacts CSL Behring
Media Contacts >
CSL Behring Social Media CSL Behring
Social Media >
CSL Behring MultiMedia Library CSL Behring
Images and Videos >



Our Patients' Stories




CSL Behring at a Glance

CSL Behring at a glance







Share
LinkedIn Twitter Facebook Google+